OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast
Get Alerts OXGN Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report second quarter 2014 results on Tuesday, August 5, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 p.m. ET (1:30 p.m. PT).
OXiGENE's earnings conference call can be heard live by dialing (888) 841-3431 in the United States and Canada, and +1 (678) 809-1060 for international callers, five minutes prior to the beginning of the call.
To listen to a live or archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors & Media" tab, select the link to "Events & Presentations."
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The Company's lead clinical product candidate, fosbretabulin (also known as ZYBRESTAT®), is in development for solid tumors. OXi4503, its second-generation product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
CONTACT: Investor and Media Contact: [email protected] (650) 635-7000Source: OXiGENE, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!